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''Immediate Seating"
for TAP Clients
Up and Running
at The AIDS Project
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by Daniel Schnorbus

The AIDS Project is happy to report the continuing
progress of our "Immediate Seating" program.
Through "Immediate Seating", clients of TAP can
request free tickets to attend cultural events in the
Portland area. These events include theater performances and choral concerts, among other events.
Various sponsors donate passes to a variety of
cultural and entertainment events throughout the year.
Among our sponsors are Maine Arts and the Maine
Gay Men's Chorus. With such donations, "Immediate
Seating" is kept vibrant. We thank our sponsors for
their generosity in the past and look forward to working
with them in the future.
If you would like to participate in the "Immediate
Seating" program, please call or visit me, Daniel
Schnorbus, at The AIDS Project and fill out an "Immediate Seating" Ticket Request Form. Please do so at
least seven days prior to the event you wish to attend.
Keep in mind that the sooner the request is made the
better the chances are of securing tickets. You will be
notified shortly after your request is made if TAP can
get tickets for you.
I look forward to hearing from you and hope to see
you in the office soon.

PROJECT

PROJECT

To contact Daniel Schnorbus, TAP's Client
Services Coordinator, call 774-6877.
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A man should stay alive if only out of curiosity.
• Yiddish proverb
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As a person who has four cats, you might think
that my favorite quote about curiosity would be
"Curiosity killed the cat." No so. The Yiddish proverb
above is more to my liking and has a more applicable
reference to my own life.
Almost thirteen years ago I suffered a very
serious bout of depression and anxiety. It was easily the
most awful time of my life. As bad as I felt, I had no
serious thoughts of suicide. Curiosity kept me going. I
just had a feeling that there was something or some
things I was meant to be around for. Facetiously I would
tell people that the thing I was meant to be around for
was the revealing of the identification of "Deep Throat",
the anonymous source for Woodward and Bernstein's
Watergate stories. The truth was more intangible.
Given that a third of my life has happened after
that terrible depression, I am of the opinion that there
have been many things I was meant to be here for, and
that there are more still to come. Many of them are
very personal and involve my family. Some are more
general and involve the world around us all. One reason
for my being here is all about being HIV-positive.
Almost eleven years ago, I tested positive for
HIV. In that time I have met an incredible number of very
fine people. Some are HIV-positive, some are not. Some
have AIDS, some have died of AIDS. I feel I was meant
to meet them all. One group in particular that I feel I was
meant to meet is a bunch of guys with HIV who banded
together in a support group and in a social way, with
dinners, cookouts, card playing, and friendship. Their
strength and perseverance has been a real lesson in the
meaning of being alive.
On New Year's Eve, it is a tradition of some of the
guys to get together and celebrate the fact that we're
still here. We meet at one of the guys' house and play
cards, eat ourselves silly, watch the ball drop in Time
Square, and stay overnight to have the first breakfast of
the new year together. We've been doing this for years.
We've lost too many of the gang to AIDS. We are
amazed and pleased to have survived. Four of us have
been around the longest. We're certainly curious why
this is so, but we don't know the answer. We would like
to be around when the answer is found, when the cure
for Al OS is found.
Personally, I still feel like there are things I am
meant to be here for. Doing this newsletter qualifies as
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one of those things. With this issue, we begin our sixth
year with the 39th edition and a collective 322 pages.
That would make a good size novel. Our first edition
came out in December 1993. We reported that Maine
had a collective 443 cases of AIDS since reporting had
begun. In this issue the number of cases is up to 832. By
December of 1993, 228 deaths from AIDS had been
reported in Maine. That figure is now 443. My curiosity
is focused on how and when those figures will cease to
become larger; how and when people will stop dying of
this disease.
If for no other reason, I might as well stay alive
out of curiosity. And I hope along the way to do some
good. My curiosity has led me into situations that have
allowed me to do some good things since testing
positive. I do a fair amount of volunteer work for The
AIDS Project by serving on its Board of Directors. It has
allowed me to have a small impact in a positive way, I
hope, to improve the agency's services for clients. It
has also given me the opportunity, as I said before, to
meet some of the most interesting people, people who
are infected and affected by HIV/AIDS.
Curiosity has been a big factor in my life. I like to
know things. I like to know how things work. I like to
know how people behave. I like to know how people
build their lives. My curiosity is like life itself -- always
happening, always adapting, always striving to survive.
As winter slows us down with its variety of
snow, sleet, rain, and freezing cold, this is the time of
year when I think about the future the most. I am very
curious about my own personal future. What will
happen to my family in the coming years? What about
my friends? What about our state and nation? And
irreverently, who is "Deep Throat"? (And even more
irreverently, if the groundhog sees his shadow, will we
have six more weeks of Clinton's Senate trial?) Who
among our gang will survive to attend next year's New
Year's Eve party?
And given all this curiosity, perhaps I am meant
to be right where I am. It's not a bad place to be, HIV
aside. Of course, it's impossible to put aside the HIV for
very long. It's always here. Still, with time has come the
realization that living with HIV is better than not living at
all. And it is better to live in spite of HIV. I guess I am just
too damn curious about what is to come to let HIV stop
me from living an interesting life.
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Robert Moore is
TAP's African-American Outreach Worker
Hi Cumberland County,
My name is Robert Moore and I am the African-American
Outreach Worker of TAP's Prevention Education Department. If you
need HIV literature, condoms, one-on-one conversation, public
speakers for educational events, and/or referrals for counseling, call
orwriteto me.
Robert Moore
The AIDS Project
P.O. Box 5305
Portland, ME 04101

Board of Directors:
PROJECT
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77 4-6877, ext. 12
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The AIDS Project
615 Congress Street - 6th Floor
(or 142 High Street)
P.O. Box 5305
Portland, Maine 04101
Phone: 774-6877 Fax: 879-0761
E-mail: tap@aidsproject.org
Website: www.aidsproject.org
AIDS Hotline: 775-1267
or 1-800-851-2437
Oxford/ Androscoggin Cty. Office
One Auburn Center/Box 14L
Auburn, ME 04210
Phone: 783-4301 Fax: 795-4084
York County Office
Lafayette Center - 4th Floor
Kennebunk, ME 04043
Phone: 985-8199
Fax: 985-8646 *51
Staff:
Doug Bailey,
HAVEN I Housing Coordinator
Declan Buckley,
MSM Outreach Worker
Diana Carrigan,
Androscoggin and Oxford Counties
Case Manager
Janine Collins,
Cumberland County Case Manager
John Cronin,
MSM Outreach Worker
Caroline Curtis,
Case Management Intern
Sequoia Dance,
Street Outreach Worker
Douglas Eaton,
Program Coord. of HIV Prevention

Denise Ferrer,
York County Case Mngmt. Intern
Jill Frame,
HAVEN Case Manager
George W. Friou,
Executive Director
Demetra Giatas,
Development Director
John Green,
HIV Case Manager
John Holverson,
Director of Policy & Program
Gloria Leach,
Community HIV Prev. Educator
Annette Lemek,
Case Management Intern
Randy May,
Director of Support Services
Robert Moore,
African-American Outreach Worker
Rebecca Neel,
Cumberland and York Counties
Case Manager
Susan Parr,
Cumberland County Case Manager
Getty Payson,
York County Case Manager
Steve Reevy,
Manager I Finance & Administration
Daniel Schnorbus,
Client Services Coordinator
Gerry Scoppettuolo,
York County Field Outreach Worker
David Aaron Swander,
Education I Development Assistant
Kerry S. Tardiff,
Admin. I Case Mngmt. Assistant
Art Waller,
Accounting Assistant
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Joel C. Martin, Esq., President
Michael Martin, Vice President
Anne M . Romano, CPA, Treasurer
JoAnne Peterson, Secretary
Lawrence Bliss
Michael Burnham
Jerrold C. Edelberg, Ph.D.
Dino Giamatti
Judi Mansing
Karla B. McGowan
Frances W. Peabody
John Wade
Christopher Warner
Verne Weisberg, M.D.
Roberta M. Wright
Advisory Board:
Bettsanne Holmes, Chair
Josiah K. Adams
Peter C Barnard
Joan B. Burns
Peter L. Chandler, CPA
Madeleine G. Corson
Maria P. Damerel
Josiah H. Drummond, Jr.
Alice Gemmer
Pamela W. Gleichman
Sandra Goolden
Celeste Gosselin
Jonathan W. Karol, D.0.
Leo J. LaPlante, CPA
Pamela Knowles Lawrason, Esq.
George M . Lord
Mallory K. Marshall
Mary Jean Mork
Gwendolyn C. O'Guin, D.0.
Patricia M. Pinto
Lois Galgay Reckitt
Victoria A. Rochefort
Lynn E. Shaffer
Elizabeth 0. Shorr
John H. Siegle, M.D.
Cynthia Sortwell, M.D.
Seth Sprague
James F. Tomney
Virginia W. Truesdale
Margaret Wiles
Jean T. Wilkinson
Margo Wintersteen
Roger F. Woodman
Frances R. Zilkha
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Wellness & You Fitness Program
for People vvith HIV/AIDS
by Daniel Schnorbus

Wellness & You is a nationally recognized stress
reduction and physical activity program designed specifically for people living with HIV and AIDS. In this program individuals can participate in a variety of supervised physical activity, education, and specialized stress
management segments. Weekly guest speakers address a
variety of stress reduction methods, ranging from massage therapy to 1neditation. Moderate physical activity,
including cardiovascular exercise and strength training,
is aimed at improving the health and well being of people
with HIV and AIDS.
Those clients interested in participating in the
Wellness & You Program will again have the opportunity
to do so starting January 25, 1999. The sessions will last
for twelve weeks and run through April 16, 1999. This
group will meet Monday, Wednesday, and Friday mornings at 10 a.m. at the Westbrook College campus of the
University ofNew England.
Individuals interested in the Wellness & You Program
can contact me, Daniel Schnorbus, at TAP at 774-6877,
or Judy Vezina, the program's facilitator, at _797-7688,
extension 4348. Please consider that there is an enrollment process that includes a health screening and fitness
assessment. Clients wishing to participate should contact
one of us as soon as possible.

Wellness
&You

l

Starts
Jan.25
Ends
April 16
Sign up

novv!
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Cases of AIDS - 832
Maine Maine
Maine Deaths from AIDS - 443
U.S. Cases of AIDS - 641,068
AIDS
U.S. Deaths from AIDS - 390,692
U P d ate Includes a11" cases smce
. reporting. began.
Maine stats as of 9/98; U.S. stats as of 12/97.
Maine AIDS Cases include only those who
resided in Maine at the time of their diagnosis.
In The Affirmative © January 1999 from Bald Man Publishing for The AIDS Project, Portland, ME
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Do Drugs Cost Too Much? Consider Testosterone May Lessen Depression in Bring HIV Campaign Out of the Dark Alley
the Alternatives
AIDS Patients
Wall Street Journal (12/15/98)
Wall Street Journal (11/14/98)
Infectious Disease News (11/98)
In a letter to the editor of the Wall Street
Richard Jay Kogan, chairman and
Researchers from the New York State Journal, Daniel Zingale, the executive director
CEO of drug company Schering-Plough, Psychiatric Institute found that biweekly of AIDS Action, applauded a recent editorial in
asserts that the increasing profits by injections of testosterone cypionate over the newspaper opposing public opinion
drug manufacturers are due to new drug three-months increased energy levels and campaigns that portray everyone as "at risk"
candidates, better medications, novel feelings of well-being in a placebo-controlled for HIV. Zingale notes that homosexual men
delivery systems, and treatments for study of 66 HIV-positive subjects. Dr. Glenn and injection drug users and their sex partners
diseases that were previously untreat- Wagner, a research scientist at the institute, are at the highest risk in the United States. He
able.
said that fatigue is fairly common in HIV- asserts, though, that limiting a campaign
Commenting in the Wall Street infected individuals, particularly those with solely to those two groups would result in a
Journal, Kogan notes that "the launch of late stage HIV. While there is no data indicating failure to reach other high risk groups,
new drugs shifts costs and benefits that anti-HIV medication decreases testoster- including young people and low-income
around in ways that confuse and one levels, other medications have been minority women.
infuriate many people." He adds that the shown to decrease hormone levels. However,
Half of the 40,000 new HIV infections in the
costs are largely borne by health plans some researchers also differentiated between United States each year occur among young
and health-care institutions. New drugs fatigue and clinical depression.
people. Zingale states that many younger
can reduce the incidence and severity of
Some researchers question whether the people are still not completely educated about
diseases on a large scale and can patient fatigue is caused by depression or by the disease, with some believing that new
increase life span for infected individu- cytokine regulation. One six-month study of 80 anti-HIV medications are capable of essenals.
people with HIV showed that length of time on tially curing infection. He adds that the drugs
The author cites the recent decline in AIDS therapy was a good predictor of are expensive and do not work for everyone.
the AIDS mortality associated with the depression, as was older age, negative
benefits of new medication. One study feelings about the future, and loss of motiva- Hospitals Get $6 Million for HIV Brain Bank
found that combination therapy for HIV tion.
Boston Globe Online (12/15/98)
resulted in a 39 percent decrease in
admissions, a 44 percent reduction in lndinavir Stones Can Persist for Long
The National Institutes of Health will give a
bed days, a 54 percent reduction in Periods in HIV-Positive Patients
$6 million grant to three New York City
serious HIV-related illness, and a 40
Reuters (01/06/99) hospitals to study the neurological effects of
percent decline in the AIDS death rate.
HIV on the brain. Mount Sinai School of
Additionally, progression to AIDS
Researchers at Walter Reed Medical Center Medicine, Beth Israel Medical Center, and St.
declined 42 percent.
in Washington, D.C., report two cases of Luke's-Roosevelt Hospital Center will in turn
While the cost of the drugs is high, prolonged indinavir-associated kidney stones create the Manhattan HIV Brain Bank, a
Kogan argues that they have reduced in HIV-positive patients who had interrupted collection of brains from people who died of
the total cost related to HIV. Attempts to indinavir treatment. In the December issue of AIDS. Researchers from around the country
decrease profits for drug companies, Clinical Infectious Diseases, Ors. Mark E. will be able to apply to the brain bank for tissue
Kogan says, may result in a decline in Polhemus and Naomi E. Aronson reported that samples.
pharmaceutical innovations.
· two HIV-positive men who stopped indinavir
Dr. Susan Morgello, the principle investigatreatment due to kidney stones still had the tor of the project, explained that "this provides
ABT-378 Shows Promise
problem after six months without the a really needed basic resource for research."
American Druggist (11/98) medication. One patient had the kidney stones The program will attempt to recruit about 90
for 11 months after indinavir treatment was people a year for the brain donations, asking
Preliminary data from a study of 35 stopped. The researchers note that while patients in the final stages of AIDS to undergo
people receiving Abbott Laboratories' indinavir cessation is the conservative neurological and psychiatric evaluation and to
ABT-378, a 2nd-generation HIV protease treatment for HIV-infected patients with donate their brains when they die. The
inhibitor, indicate that the drug can be kidney stones, not all cases resolve with researchers hope to identify whether HIV can
used to successfully lower viral loads. In conservative treatment, and physicians latently infect the brain and nervous system,
the study, 16 of 17 treatment-naive should strongly consider withdrawing to determine the impact of brain infection with
people receiving the medication in indinavir with any episode of indinavir- HIV, and to devise new drug therapies against
conjunction with ritonavir had their viral associated kidney stones.
HIV and HIV-associated disorders.
loads fall to 400 copies per ml or lower
over 20 weeks of therapy. Co administration with ritonavir increased
the bioavailability of ABT-378. Kim
Madory, a spokesperson for Abbott,
said that it could still be months before
phase Ill trials begin.

"Hope sees the invisible, feels the intangible,
and achieves the impossible."
- Anonymous
;-'- .~ .
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HIV Type 1 in Semen of Men Receiving Challenging the
Highly Active Antiretroviral Therapy
Conventional Stance on Al DS
New Eng. Jml. of Med. (12/17/98)
New York Times (12/22/98)

Controversy Rages Over Reporting Naming
Names of HIV-positives
Seattle Times Online (12/28/98)

Researchers from Thomas Jefferson
University in Philadelphia, Pa., detected
proviral DNA from HIV in the seminal
cells of HIV-1-infected men receiving
highly active antiretroviral therapy who
had no detectable levels of viral RNA in
their plasma. The finding suggests that
the virus can be sexually transmitted by
infected men who appear to be in
remission.
The researchers, led by Dr. Hui Zhang,
found proviral DNA in the seminal cells
of four of seven men tested. Two men
showed replication-competent viruses
in their seminal cells. According to the
researchers, Uthe viruses recovered
from the seminal cells had no genotypic
mutations suggestive of resistance to
antiretroviral drugs and were
macrophage-tropic, a feature that is
characteristic of HIV-1 strains that are
capable of being sexually transmitted."

Across the nation, debate is raging over the
use of name reporting for HIV-infected people.
Texas has decided to abandon the use of
unique identifier codes that allow for anonymous HIV surveillance, instead opting to
report cases by name. Texas tried the nonname based reporting system for four years.
Many AIDS activists are in favor of the
unique identifier system for the sake of patient
confidentiality. Maryland has used the system
as long as Texas, reporting no problems with
its surveillance ability. Thirty-two states thus
far have adopted some form of HIV reporting,
but Texas and Maryland are the only two that
used unique identifiers.
Proponents of non-name based testing
assert that the reporting of names will result in
a decrease in the number of people willing to
gettested for HIV.
However, Surgeon General David Satcher
notes, "Using names discourages testing only
for those who don't understand the system.
What they see as a risk is greatly exaggerated."
The Centers for Disease Control and
Prevention recently recommended the use of
name-based reporting, but leaves the decision
up to individual states.

Glaxo Wins Approval for New AIDS
Drug Despite Serious Risks
Wall Street Journal (12/21/98)
Glaxo Wellcome's newest AIDS drug,
Ziagen, was approved for marketing by
the Food and Drug Administration, even
though clinical trials showed that about
5 percent of patients experienced
significant, and in some cases, fatal side
effects, including fever, nausea,
abdominal pain, low blood pressure, and
an enlarged liver.
Despite the potential drawbacks, the
FDA approved Ziagen because it is used
to treat a life-threatening disease and
may allow some patients to discontinue
the use of drug ucocktails" that are the
standard in AIDS treatment today.
While many patients currently take as
many as 20 pills a day, patients who can
tolerate Ziagen in combination with
another AIDS drug, such as Glaxo's
Combivir, would have to only take about
four pills a day. Ziagen, a nucleoside
analogue reverse transcriptase inhibitor,
is the fourth AIDS drug Glaxo has
developed.

Conspiracy theories about HIV still abound
despite a wealth of available scientific
evidence. Recently, the Rev. Al Sharpton and
his National Action Network sponsored the
Harlem AIDS Forum, which featured many
outspoken opponents to traditional views on
HIV and AIDS. Of approximately 12 speakers,
only one believed that HIV is the cause of
AIDS, but he also argued that the virus was
being spread to people of color throughout the
world through the World Health Organization
via its vaccine programs. Event organizer
Curtis Cost explained that the objective of the
meeting uwas to allow people to hear
disparate perspectives, and to do their own
research."
According to a survey conducted by the
Institute of Minority Health Research at Emory
University's Rollins School of Health, 74
percent of African-Americans questioned
believed they were very likely or somewhat
likely to be used as test subjects for studies
without their consent. Eighteen percent
reported that they believe that HIV was an
engineered virus and almost 10 percent said
that AIDS is part of a genocidal plot to kill black
people.
The AIDS epidemic has been particularly
prevalent in the African-American community;
although African-Americans comprise only 13
percent of the United State's total population,
they accounted for 57 percent of new
infections last year, according to the Centers
for Disease Control and Prevention. Some
AIDS activists among the community
disapprove of the conspiracy theories,
asserting that they serve to subvert prevention
efforts such as testing and safe sex.

"While there is a chance of
the world getting through its
troubles, I hold that a reasonable man has to behave as
though he were sure ofit. If at
the end your cheerfulness is
not justified, at any rate you
will have been cheerful."

Role of HHV-8 in HIV-Related Kaposi's
Sarcoma Confirmed
Reuters (12/29/98)
Researchers from the Amsterdam Cohort
Studies on HIV Infection and AIDS report data
that "strongly confirm" the causal role of
human herpesvirus-8 (HHV-8) in Kaposi's
sarcoma (KS). The authors studied over 1.400
homosexual men and more than 1, 100 drug
addicts to determine the presence of
antibodies to HHV-8 antigens.
According to the findings, there was a low
prevalence of HHV-8 seropositivity among
drug users with a low incidence of KS, while
the high prevalence of HHV-8 seropositivity
among the homosexual men paralleled a high
incidence of KS in that cohort. The study was
reported in the Dec. 24 issue of AIDS.

-H. G. Wells
In The Affirmative © January 1999 from Bald Man Publishing for The AIDS Project, Portland, ME
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Court Faults Dentist in HIV Dispute
Washington Post (12/31/98)
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Patient or Guinea Pig?
Dilemma of Clinical Trials
New York Times (01/05/99)

A U.S. Appeals Court ruled that Maine
dentist Randon Bragdon violated the
1990 American with Disabilities Act by
refusing to treat an HIV-infected woman
in his office for fear of contracting the
disease. Bragdon had suggested filling
the woman's cavity in a hospital instead,
which he said would offer greater
precautions against HIV infection;
however, Sidney Abbott refused
because the in-hospital procedure
would have cost her $185, while the
office procedure would have been just
$35.
The case reached the appeals court
after the Supreme Court sent it back for
reconsideration. The dentist's attorney
noted that the Supreme Court, which
ruled in June that HIV-infected individuals are protected by the ADA, unless
they pose "a direct threat to the health
and safety of others," may be asked to
reconsider his client's case. Under
federal law, Bragdon may be held liable
for Abbott's legal expenses.

Clinical trials sometimes entail ethical
dilemmas because the purpose of many
studies is not to help treat patients but to
gather information that could eventually help
others. However, many people who sign up for
trials view the experimental drugs as
beneficial treatments, despite the fact that the
drugs may not help the subject.
George Annas, chairman of the health law
department at Boston University School of
Public Health, explains that "sick people can't
think of themselves as research subjects.
They don't want to feel like they're being used
as guinea pigs." Some patients become
involved in the trials because they cannot
afford other treatment. In addition, some AIDS
and hepatitis C advocacy groups have taken
up treatment issues, supporting the rights of
subjects involved in clinical trials.
In one study of a hepatitis Ctreatment, viral
load results were withheld until the trial's end
in order to retain as many subjects as possible.
Advocates believe that the practice is
unethical because it limits treatment options
and does not allow patients to assess their
Peripheral Neuropathy/Myopathy progress. The practice is not found in HIV
Common Side Effects of HIV clinical trials due to the strong advocacy
groups and community advisory groups
Antiretrovirals
Reuters (12/30/98) available to HIV-infected individuals.

Members of an AIDS Clinical Trials
Group report that therapy with currently
recommended antiretroviral drugs for
HIV infection could produce symmetrical neuropathy (nerve disease) and
myopathy (skeletal muscle disease). Of
nearly 2,500 patients studied, 222 site
diagnoses of neuropathy were made,
about half of which were cases of distal
symmetrical neuropathy. Patients
receiving zidovudine and zalcitabine had
the highest rates of distal symmetrical
neuropathy.
The researchers, who reported their
findings in the Dec. 24 issue of AIDS,
said that because neuromuscular
complications are common
antiretroviral therapy-related effects,
dose modifications may be required.
A Correction
In last month's newsletter, I spelled Kerry
Tardiff's name incorrectly-- twice and in different
ways both times. My apology to Kerry and my
thanks for her fine work on getting this newsletter
distributed to all our readers.

Dual HIV Infection Cases Not So Rare
AIDS Alert (12/98)
Scientists previously believed that dual
infection with multiple strains of HIV occurred
only in rare cases, but new data show that
dual-infection cases may be more common
than formerly thought. Researchers in
Alabama investigated HIV-infected chimpanzees that were exposed to an unrelated HIV-1
strain. Using PCR tests of cellular DNA from
blood and lymph nodes, the researchers found
that they could identify the second strain, but
only within the first six weeks of exposure to
the second HIV strain.
According to Dr. Fultz, one of the researchers, the finding "indicated that the prior
infection was down-regulating and bringing
under control the second strain that the animal
was exposed to, which is what you would like
in a vaccine." Even universal primers did not
pick up the second strain in some animals.
Using PCR primers to the strains that had
infected the animals, the scientists found that
almost every animal was, in fact, infected with
a second strain, indicating that primers
preferentially pick up one strain. Fultz said she
is not optimistic about the ability of existing
methods to detect secondary strains.
AIDS Vaccines Look Good in Tests
San Francisco Examiner Online {12/27/98)

Even though several AIDS experts are
Increase in Heterosexually Acquired HIV confident that developing a vaccine against
Infection Validated
AIDS by President Clinton's goal of 2007 is an
Reuters (01/05/99) attainable objective, a NIH report that said that
creating an effective vaccine will require a
Researchers from the CDC report in the tremendous undertaking has received the
January issue of the American Journal of support of researchers such as R. Scott Hitt,
Epidemiology that most patients with chairman of Clinton's advisory council on
heterosexually acquired AIDS have a valid HIV/AIDS, who believes that developing a
heterosexual risk of exposure to HIV, support- vaccine within 10 years will take more effort or
ing reports of an emerging heterosexual AIDS good luck. Anthony Fauci, director of the
epidemic in the United States. Researchers at NIAID, and an advocate of Clinton's goal, has
the CDC investigated heterosexual risk among pointed out that one of three vaccines in latealmost 2,000 patients (aged 13 years or older) stage development could be the first to make a
who reported heterosexual risk or no risk for breakthrough, including VaxGen's AIDSVax,
HIV infection; heterosexual risk was validated which is in Phase Ill trials to determine
in 82 percent of the subjects.
whether the antibodies stimulated by the
About one-fifth of the men and over half of genetically engineered vaccine attack HIV.
the women who initially reported no risk Using a different approach, Wyeth-Lederle
factors for the virus were determined to have Vaccines is developing a vaccine that involves
most likely contracted HIV heterosexually. The injecting a small amount of HIV DNA into a
CDC suggests that heath care workers make person's muscle to stimulate the production of
determined efforts to identify and record antibodies against the virus. Pasteur-Merieux
accurate information for people infected with Connaught is working on a so-called vectored
HIV and that there be periodic re-examination vaccine, currently in Phase II trials. '"A ~
of patient risk factors to ensure data accuracy.
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Enjoy a free lunch at The AIDS Project every Thursday at noon. CL

Join other clients and TAP staff for a great meal, good conversa:::)
tion, and very good company. Drop on by Thursdays at noon!

(/)

IMMEDIATE SEATING
For free tickets to area events as they become available, sign up
for "Immediate Seating." Call TAP at 774-6877 for more
information.

I.V LEAGUE
Meetings of the I.V. League support group are held on
Wednesdays at 11 :00 a.m. at the Parkside Community Center,
94 Mellen Street, in Portland.
For more information, call 874-8775.

THE MEETING PLACE
This room is used by TAP in Portland for support groups,
counseling and testing, and some client/case manager
meetings. Located in Suite 632, it provides more privacy for
people served by TAP.
Enter from the High Street side of the building.

2

Q

PROJEtT

An important reminder to clients:
::::) FOR PEOPLE INFECTED
There are funds available to TAP clients with financial need for
AND AFFECTED BY HIV/AIDS
the following items: Routine Dental Care, Routine Eye Care and
Eyeglasses, Vitamin Supplements, Non-Prescription Skin Care
Products, and Non-Medicaid Medication Co-pays.
Time: 10:30 a.m. to noon
There is a dollar limit to how much a client can receive in any
fiscal year. Contact your case manager for assistance.
J- Group: HIV Infected/Affected Drop-In Support Group

!z FREE LUNCH
UJ

en

a.

TAP ON-LINE

A meeting for people living with and affected by the virus.
Location: Portland, TAP, The Meeting Place, Suite 632.
Contact Randy May at TAP at 77 4-6877 for more info.

Time: 1:30 p.m. to 3:00 p.m.
Group: People Living with HIV
A drop-in support group for people living with HIV.
Location: Auburn, TAP, One Auburn Center.
Contact Diana Carrigan at TAP at 783-4301 for more info.

THURSDAYS
Time: 10:00 a.m. to 11 :30 a.m.
Group: HIV Infected/Affected Drop-in Group
A TAP-sponsored meeting for people
living with and affected by HIV/AIDS in southern Maine.
Location: Sanford, Unitarian Church, located at the corner
of Main St. (Rte. 109) and Lebanon St. (Rte. 202).
Contact Getty Payson at TAP at 985-8199 for more info.

Time: 12 noon
Group: Open Lunch for TAP Clients/Staff
An informal luncheon gathering ofTAP staff and clients.
Location: Portland, TAP, Conference Room.
Contact Randy May at TAP at 77 4-6877 for more info.

Visit our new website at "www.aidsproject.org"

_

To e-mail The AIDS Project,

Time: 5:30 p.m. to 7:00 p.m.

L-

send your message along to ''tap@aidsproject.org"

0U.

www.hivpositive.com
www.thebody.com
www.projinf.org
for info on HIV and AIDS.

Group: People Living with HIV/AIDS
A drop-in support group for anyone with HIV/AIDS.
Location: Portland, TAP, The Meeting Place, Suite 632.
Contact Randy May at TAP at 77 4-6877 for more info.

ja: ~:~k~~!~~!i~~

i; AIDS HOTLINES
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Questions about HIV/AIDS?
Call toll-free
National AIDS Hotline:

>-

1-800-342-2437

0

Maine Teen Hotline:

a:

LL

Maine AIDSline:

1-800-851-2437
1-800-851-2437
(on Wednesdays from 6-9pm)

IN THE AFFIRMATIVE
In The Affirmative is a monthly newsletter published
by The AIDS Project for people living with and affected
by HIV/AIDS. Letters, articles, or other submissions
should be sent to: In The Affirmative, c/o The AIDS
Project, P.O. Box 5305, Portland, ME 04101, or call
(207) 774-6877 . Submissions can be printed
anonymously as long as the person submitting the
material includes his or her name and phone number for
verification.
News, information, and features are as up-to-date
as possible prior to publication. Any medical
information included in this newsletter is submitted for
the reader's information only, to be used as the reader
so chooses.
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Sources for some of the information in this
newsletter include:
CDC HIV/STD/TB Prevention News Update
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Janine Collins
Robert Moore
Daniel Schnorbus
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